Methoxetamine

Methoxetamine, sold as MXE, is a ketamine analogue carrying a methoxy group in place of the chlorine and an N-ethyl group in place of the N-methyl. It reached the research chemical market around 2010 accompanied by a specific marketing claim: that it was a ketamine substitute without ketamine's bladder toxicity. That claim was never supported by evidence, and urinary problems were subsequently reported with MXE as well.

Pharmacologically it is a potent NMDA receptor antagonist, and its major metabolites are potent NMDA antagonists in their own right, which is part of why its effects run long ^[7]. It differs from ketamine in also acting on the serotonin transporter, which is the usual explanation offered for its more hallucinogenic character ^[5]. Detailed behavioural, pharmacokinetic and metabolic characterisation in rats mapped its profile properly for the first time ^[8], and its metabolic pathways were described separately ^[9].

The animal safety data is the part that deserves weight. Repeated administration in rats produced persistent behavioural abnormalities and evidence of neurotoxicity, which is a finding ketamine's own literature does not straightforwardly match ^[10]. MXE was associated with deaths and hospital presentations during its period of widest availability and was brought under control in the United Kingdom and elsewhere from 2012 onward.

MXE is more potent and longer than ketamine, so misjudging exposure is easy, and heavy or frequent use was associated with dissociative toxicity, high blood pressure, and cerebellar signs (balance and coordination problems). Its serotonin activity makes MAOIs and strong serotonergics dangerous (serotonin toxicity), and it stacks badly with other depressants. Not medical advice.

Methoxetamine appeared around 2010, one of the first arylcyclohexylamines designed specifically for the research chemical market rather than adapted from pharmaceutical research. It was sold with an explicit selling point, that it avoided the urinary tract damage associated with heavy ketamine use, and that claim was made in advance of any evidence and never substantiated.

Uptake was fast and so was the harm signal. Hospital presentations and deaths involving MXE accumulated over the following two years, and reviews of the period describe a novel recreational drug with potent hallucinogenic properties and a poorly understood toxicity profile ^[5]. The United Kingdom placed it under a temporary class drug order in 2012 and controlled it permanently in 2013, with other jurisdictions following; it was cited in the same period as an example of how quickly the novel psychoactive substance market could move ^[11]. It was also noted specifically as a designer drug of concern for military readiness ^[12].

The pharmacology arrived after the controls, which is the usual order for this class. Its metabolites and metabolic pathways were characterised in 2014 ^[9], a detailed behavioural, pharmacokinetic and metabolic evaluation in the Wistar rat followed in 2016 ^[8], evidence of persistent behavioural abnormality and neurotoxicity after repeated dosing was published in 2019 ^[10], and the finding that its major metabolites are themselves potent NMDA blockers came in 2022 ^[7].

MXE is the cautionary tale of the dissociative research chemical market, and it is worth knowing as one. It was sold on a harm-reduction promise, that it was the bladder-safe ketamine, which was never demonstrated and did not survive contact with use; urinary problems were reported with it too. Anyone encountering the same claim attached to a newer analogue is encountering the same marketing.

Among users its reputation was for being more hallucinogenic and more disorienting than ketamine, with a notably delayed onset, and that delay is implicated in a great deal of the harm: a compound that takes a long time to arrive gets redosed before it has. Its effects also run considerably longer than ketamine's, which the metabolite pharmacology explains, since the major metabolites block NMDA receptors potently themselves ^[7].

Scientifically its standing now rests on the rat data, and that data is unflattering. Repeated administration produced persistent behavioural abnormalities and neurotoxicity ^[10], which is a more specific and more concerning finding than a general warning about an unstudied compound. It is largely off the market, having been controlled in most jurisdictions, and is now mostly encountered in the literature rather than in circulation.